To the best of our knowledge, this is the first CHARGE syndrome in Chinese patients diagnosed by gene
analysis, in which a de novo truncated CHD7 mutation was identified. Most of the patients with CHARGE
syndrome reported to date, which were identified by genetic diagnosis, were from the western countries,
and there are also several cases reported in Korea (Cho et al., 2013) and Japan (Aramaki et al., 2006).
However, without genetic diagnosis, CHARGE syndrome in China was difficult to diagnose and often
considered as an incurable disease. Before our study, only two cases probably suspected as CHARGE
syndrome according to the clinical symptoms were reported, but without further verification (Qu et al.,
2010). Therefore, the clinical symptoms and pertinent treatment in the present case, combined with
genetic analysis and functional prediction of CHD7, fill the gap of genetic diagnosis of CHARGE syndrome
in Chinese patients, and suggests that identifying the underlying genetic defects in patients with CHARGE
syndrome is helpful for accurate diagnosis, appropriate treatment, and genetic counseling.
To the best of our knowledge, this is the first CHARGE syndrome in Chinese patients diagnosed by gene
analysis, in which a de novo truncated CHD7 mutation was identified. Most of the patients with CHARGE
syndrome reported to date, which were identified by genetic diagnosis, were from the western countries,
and there are also several cases reported in Korea (Cho et al., 2013) and Japan (Aramaki et al., 2006).
However, without genetic diagnosis, CHARGE syndrome in China was difficult to diagnose and often
considered as an incurable disease. Before our study, only two cases probably suspected as CHARGE
syndrome according to the clinical symptoms were reported, but without further verification (Qu et al.,
2010). Therefore, the clinical symptoms and pertinent treatment in the present case, combined with
genetic analysis and functional prediction of CHD7, fill the gap of genetic diagnosis of CHARGE syndrome
in Chinese patients, and suggests that identifying the underlying genetic defects in patients with CHARGE
syndrome is helpful for accurate diagnosis, appropriate treatment, and genetic counseling.
การแปล กรุณารอสักครู่..

To the best of our knowledge, this is the first CHARGE syndrome in Chinese patients diagnosed by gene
analysis, in which a de novo truncated CHD7 mutation was identified. Most of the patients with CHARGE
syndrome reported to date, which were identified by genetic diagnosis, were from the western countries,
and there are also several cases reported in Korea (Cho et al., 2013) and Japan (Aramaki et al., 2006).
However, without genetic diagnosis, CHARGE syndrome in China was difficult to diagnose and often
considered as an incurable disease. Before our study, only two cases probably suspected as CHARGE
syndrome according to the clinical symptoms were reported, but without further verification (Qu et al.,
2010). Therefore, the clinical symptoms and pertinent treatment in the present case, combined with
genetic analysis and functional prediction of CHD7, fill the gap of genetic diagnosis of CHARGE syndrome
in Chinese patients, and suggests that identifying the underlying genetic defects in patients with CHARGE
syndrome is helpful for accurate diagnosis, appropriate treatment, and genetic counseling.
การแปล กรุณารอสักครู่..
